Method for synthesizing copper oxide nanoparticles, cuo-nps, using inula viscosa and applications thereof in wound care
CuO-NPs synthesized from Inula viscosa address the limitations of current dressings by providing antibacterial and anti-inflammatory properties, enhancing wound healing through biocompatible dressings and medical devices.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- UNIV SIDI MOHAMED BEN ABDELLAH
- Filing Date
- 2026-01-23
- Publication Date
- 2026-07-23
Smart Images
Figure IMGF000011_0001 
Figure IMGF000010_0001_TABLE 
Figure 00000017_0000
Abstract
Description
[0001] Description
[0002] technical field
[0003] The present invention relates to an environmentally friendly process for synthesizing copper oxide nanoparticles (CuO-NPs) using the medicinal plant Inula viscosa, within the framework of nanotechnology research applied to biomedicine. It also explores the applications of these nanoparticles as wound-healing, anticoagulant, and anti-inflammatory agents. More specifically, the present invention relates to the use of these CuO-NPs in wound care products such as dressings impregnated with these nanoparticles, intended to promote healing and to treat or prevent microbial infections.
[0004] Description of the state of the art in interior design
[0005] Wound healing is a complex process primarily aimed at promoting closure, particularly for open skin wounds such as burns, trauma, neuropathic ulcers, pressure ulcers, and venous ulcers. These types of wounds represent a major clinical challenge due to their complexity, as well as a considerable burden with significant social and economic implications. The healing process generally unfolds in six interdependent phases: inflammation, fibroblast proliferation, angiogenesis, connective tissue synthesis, epithelialization, and wound contraction. Disruption in any of these stages can lead to wound healing failure, severe complications, and increased costs for the healthcare system.
[0006] While current dressings represent a valuable therapeutic approach, they do have limitations, particularly in terms of infection control and biocompatibility. Therefore, it is essential to develop innovative dressings that not only improve wound healing efficiency and reduce fluid loss, but also accelerate the healing process by minimizing infection and wound adhesion. These new solutions could incorporate materials with enhanced antimicrobial properties and improved interaction with biological tissues, thus contributing to optimal healing.
[0007] With this in mind, several patents have explored innovative solutions for manufacturing more effective dressings. For example, US patent 6140257 describes the use of absorbent composite fibers containing alginate and a polysaccharide, which allows for better moisture management in dressings. Other patents, such as US 20130330417 A1, mention the use of chemically modified cellulose fibers, alginate, and chitosan to improve the absorption and antimicrobial capacity of dressings.
[0008] Metallic nanoparticles, particularly silver nanoparticles, are also central to many innovations in modern wound dressings. US Patent 20120282348 A1 describes the use of silver hydrogels for treating burns, thanks to their ability to regulate moisture while providing antibacterial properties. Similarly, US Patent 7704523 B2 highlights the use of microbial cellulose for treating chronic wounds, leveraging its natural biocompatibility and tissue regeneration properties. US Patent 20130211308 A1 goes further by combining bacterial cellulose with silver nanoparticles, thereby improving both exudate absorption and antimicrobial activity.
[0009] One of the most promising solutions lies in green synthetic metallic nanoparticles, particularly those based on copper oxide. These nanoparticles are manufactured from plant extracts, reducing environmental impact and eliminating the use of toxic chemicals. This process is particularly advantageous, as demonstrated by patents such as KR 20190072716A, CN 106623972A, and CN 105965031 A, which show how metallic nanoparticles can be rapidly prepared using plant extracts like turmeric or extracts of Chinese goji berry and Fructus lycii, respectively, and could be used for biomedical applications thanks to their nanoscale size and lack of chemical residues.
[0010] One of the most advantageous characteristics of CuO-NPs is their antimicrobial activity. These properties help prevent infections, a crucial factor for wound healing. Although copper has a lower bactericidal potency compared to other metals, it stands out for its low cost, its tolerability by the body, and its role as an essential micronutrient. This allows for the administration of higher doses without the risk of major adverse effects. US 10016525B2 describes antimicrobial compositions based on functionalized copper nanoparticles, which can be used to improve wound healing while controlling infections. The formulation of copper as oxide nanoparticles not only enhances its efficacy but also increases its bioavailability, thus facilitating its integration into clinical treatments.To ensure their therapeutic efficacy, CuO-NPs must meet specific criteria. The size of the nanoparticles must be carefully controlled to guarantee optimal distribution within tissues and effective interaction with cells involved in the healing process. The stability of the nanoparticles in a biological environment is also crucial to prevent aggregation, which could diminish their effectiveness. Furthermore, these nanoparticles must be biocompatible, non-toxic, and must not induce undesirable immune responses, in order to create an environment conducive to healing.
[0011] In summary, green synthetic metallic nanoparticles offer promising prospects for wound treatment, combining healing and antimicrobial properties with a sustainable approach.
[0012] Description of the invention
[0013] The use of metallic nanoparticles in medicine has garnered increasing interest in recent years, particularly for wound treatment. Due to their unique properties at the nanoscale, such as their large specific surface area, their ability to penetrate biological tissues, and their potent antimicrobial effects, metallic nanoparticles represent a promising solution for improving wound healing.
[0014] The emergence of green synthesis of metallic nanoparticles—that is, their production from plant extracts or other biological sources—represents a major turning point in this field. Unlike conventional methods that can involve toxic or polluting reagents, green synthesis is not only more environmentally friendly, but it also allows for the production of nanoparticles with improved properties in terms of biocompatibility, biodegradability, and acceptability by biological tissues.
[0015] In this context, the present invention proposes a method for synthesizing CuO-NPs using a plant known for its medicinal properties, namely Inula viscosa. The synthesis of CuO-NPs using a plant extract involves preparing a solution of copper(II) sulfate pentahydrate (CuSO4-5H2O) as a precursor, and an extract of the Inula viscosa plant or a part thereof, which serves as a reducing and stabilizing agent. The solutions are then combined to obtain a reaction mixture, which is incubated under optimal conditions to promote the formation of CuO-NPs. Indeed, the CuO-NPs obtained according to the method of the present invention have shown good hemocompatibility with remarkable anticoagulant and wound-healing properties. Their ability to interact favorably with blood cells, modulate coagulation, and stimulate fibroblast proliferation makes them promising candidates for biomedical applications.Furthermore, their anti-inflammatory activity has also been demonstrated, contributing to the reduction of inflammation in damaged tissues. These characteristics add significant value to CuO-NPs, offering new perspectives for their use in wound healing treatments and wound management.
[0016] Furthermore, the invention also relates to the example of direct impregnation of sterile dressings with CuO-NPs for wound treatment. Dressings containing these nanoparticles have demonstrated effective antibacterial properties against germs frequently associated with wound infections. These antimicrobial properties not only enhance the effectiveness of the dressings in preventing infections but also their ability to accelerate wound healing by maintaining a healthier local environment. The characteristics of the CuO-NPs thus formed are detailed in the following figures.
[0017] Brief description of the figures
[0018] Figure 1 represents the UV-Vis absorption spectrum of CuO-NPs synthesized from Inula viscosa after incubation under optimal conditions according to the present invention.
[0019] Figure 2 is the image of the CuO-NPs synthesized from an aqueous extract of Inula viscosa obtained by scanning electron microscopy SEM according to the present invention.
[0020] Figure 3 illustrates the energy-dispersive X-ray absorption spectrum of CuO-NPs synthesized from an aqueous extract of Inula viscosa according to the present invention.
[0021] Figure 4 represents the spectrum of the Fourier Transform Infrared (FTIR) spectroscopy analysis of CuO-NPs synthesized with Inula viscosa extract according to the present invention.
[0022] Figure 5 shows the effect of CuO-NPs synthesized according to the present invention from an aqueous extract of Inula viscosa on the proliferation of dermal fibroblasts isolated from rats. Figure 6 reveals the hemolytic activity of biogenic CuO-NPs, at various concentrations, obtained according to the present invention under hemocompatibility testing. Distilled water is used as a positive control. Figure 7 illustrates the anti-inflammatory effect of CuO-NPs synthesized according to the present invention from an aqueous extract of Inula viscosa on the inhibition of bovine serum albumin (BSA) denaturation.
[0023] Figure 8 shows the SEM scanning electron microscopy images of untreated sterile dressings and those impregnated in situ with CuO-NPs synthesized from Inula viscosa according to the present invention.
[0024] Figure 9 shows the image of the antibacterial activity of CuO-NP coated dressings synthesized according to the present invention using the aqueous extract of the Inula viscosa plant.
[0025] Detailed description of the invention
[0026] 1- Synthesis and characterization of Nanoparticles
[0027] The first part of the present invention relates to a process for synthesizing nanoparticles with healing and antibacterial properties, based on the combination of a CUSO4-5H2O solution with an extract of the Inula viscosa plant, which can be in aqueous form, in order to generate CuO-NPs
[0028] The preparation of the plant extract is carried out using one or more parts of the plant, such as the leaves, roots, or stems. Before extraction, the plant parts are thoroughly washed, dried, and then ground into a fine powder. This powder is then mixed with water or other organic solvents at a minimum concentration of 10%, and the mixture is stirred to facilitate extraction. After a settling period, the mixture is filtered to recover the Inula viscosa extract.
[0029] In parallel, a CuSO4-5H2O solution is prepared. The next step involves combining the Inula viscosa extract with the CuSO4-5H2O solution, thus forming the CuO-NPs solution. Under optimal synthesis conditions, and after a reaction of at least 30 minutes, a color change in the mixture is observed, shifting from yellow-green to dark brown. This change indicates the formation of CuO-NPs.
[0030] The nanoparticles thus obtained have a spherical shape and an average size of about 85 nm. They were characterized by several analytical techniques, including SEM, UV-Vis spectroscopy, EDX and FTIR, allowing evaluation of their size, shape and other structural properties, as detailed below.
[0031] The synthesized CuO-NPs exhibit biocompatible, anticoagulant, wound-healing, and anti-inflammatory properties, making them promising for applications in medical dressings. They have also demonstrated significant antibacterial effects against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, further enhancing their potential for treating skin infections.
[0032] Example 1: Preparation of the aqueous extract of Ioula viscosa
[0033] Healthy leaves of the Inula viscosa plant were first harvested and thoroughly washed with tap water, then with distilled water to remove impurities. After washing, the leaves were dried at room temperature, maintaining a stable environment between 15 and 25 °C. This drying phase was essential to preserve the vital properties of the leaves before they were ground into a coarse powder.
[0034] Next, 10 to 20 g of crushed leaves was measured and mixed with 100 ml of distilled water. This mixture was stirred continuously at room temperature for at least two hours, allowing for optimal extraction of the plant's bioactive components.
[0035] Once the extraction period was complete, the mixture was centrifuged at 10,000 rpm, facilitating the separation of the liquid supernatant from the solid residue. The supernatant was then carefully filtered through Whatman No. 1 filter paper, followed by further filtration using a 0.45 µm nitrocellulose filter to ensure the complete removal of any residual particulate matter. Finally, the purified extract was stored at 4°C until use.
[0036] Example 2: Biosynthesis of copper oxide nanoparticles using Inula viscosa leaves
[0037] CuO-NPs were synthesized from a 10 mM aqueous solution of CuSCU-SlUO. The process involved mixing an aqueous extract of Inula viscosa with this copper sulfate solution at a ratio of 1:4 (v / v) and then stirring the mixture overnight. The solution was subsequently heated to 80 °C for 2 hours to ensure complete reduction of the copper ions.
[0038] This process resulted in a color change in the solution, from an initial blue to a yellow-green hue, which gradually deepened to dark brown after at least 30 minutes of incubation. This color change served as a visual indicator of CuO-NP formation. Once the reaction was complete, the mixture was centrifuged at 12,000 rpm for 10 minutes. The resulting precipitate was washed repeatedly with distilled water to remove impurities and then dried at 60 °C for 24 hours to prepare it for further analysis.
[0039] Example 3: Characterization of copper oxide nanoparticles obtained from Inula viscosa
[0040] Confirmation of CuO-NP synthesis via the Inula viscosa plant, according to the process described in the present invention, was initially ensured by a visual indicator. The color of the reaction mixture changed from an initial blue to a yellow-green hue, then gradually turned dark brown after a minimum incubation of 30 minutes. Subsequently, the nanoparticles were thoroughly characterized using appropriate analytical techniques. UV-Vis spectroscopy confirmed the presence of the nanoparticles by providing an absorption spectrum in the 250–600 nm range, as illustrated in Figure 1. Maximum absorption was observed at 375 nm after 24 h, thus validating the formation of the nanoparticles.
[0041] SEM microscopy was used to examine the morphology and size distribution of the nanoparticles. The resulting image, shown in Figure 2, indicates that the nanoparticles were spherical and ranged in size from 50 to 110 nm. Furthermore, EDX spectroscopy was performed to determine the elemental composition of the nanoparticles. The results, illustrated in Figure 3, revealed the presence of copper and oxygen, as well as other elements such as carbon and silicon, thus confirming the presence of CuO-NPs.
[0042] FTIR spectroscopy was also used to analyze the functional groups coating the surface of these nanoparticles. The results indicated the presence of characteristic functional groups such as carbohydrates, phenolic groups, and carboxylic acids. These active groups may be responsible for the stability and observed properties of the synthesized CuO-NPs, as shown in Figure 4.
[0043] In view of all these characterization results, the present invention asserts that the Inula viscosa leaf is a good source for the synthesis of CuO-NPs.
[0044] Example 4: Evaluation of the biocompatibility of CuO-NPs Inula viscosa
[0045] To evaluate the blood compatibility of the nanoparticles obtained according to the process described in the present invention, an in vitro red blood cell hemolysis test was performed. This evaluation consisted of measuring hemoglobin levels after exposure of erythrocytes to various concentrations of CuO-NPs, ranging from 1 to 1000 pg / ml.
[0046] For this test, a 10% red blood cell solution was prepared in isotonic phosphate buffer (pH 7.4) and then mixed with CuO-NPs at the different concentrations tested. The mixture was incubated for 60 minutes at 37°C and then cooled to room temperature before being centrifuged at 2500 rpm for 5 minutes. The absorbance of the supernatant was then measured at 540 nm to determine the degree of hemolysis. Distilled water was used as a positive control, and identical conditions were applied to this solution.
[0047] The results obtained indicate that the hemolytic potential of CuO-NPs is dose-dependent (Figure 5). At low concentrations, these nanoparticles show no hemolytic activity. However, the maximum concentration tested induces slight, non-significant hemolysis reaching 10.48%. These results, in accordance with the standard classification of the American Society for Testing and Materials (ASTM), suggest that although CuO-NPs do not cause damage at concentrations below 1 mg / ml, these levels remain low compared to cells treated with distilled water, which serves as a positive control.
[0048] Therefore, CuO-NPs synthesized from Inula viscosa exhibit good blood compatibility at concentrations below 1 mg / ml, making them safe for various medical applications. Their low hemolytic potential allows their use in biomedical devices such as stents, catheters, prostheses, and controlled drug delivery systems. They could also be incorporated into biomedical bandages and smart dressings for tissue repair and wound healing. Furthermore, their low toxicity and favorable interaction with blood cells open up possibilities for applications in cancer therapies, particularly for targeted drug delivery or gene therapy.
[0049] Example 5: Healing effect of CuO-NPs produced by Inula viscosa
[0050] The present invention also evaluated the in vitro wound-healing effect of CuO-NPs produced by Inula viscosa on a primary culture model. To this end, dermal fibroblasts isolated from rats were cultured in the presence of these nanoparticles, and their proliferative activity was measured using the MTT assay. The results presented in Figure 6 show that no significant difference was observed in the proliferation of fibroblasts treated with concentrations of 50 and 100 pg / ml, compared to the control group of untreated cells. In contrast, an increasing concentration of CuO-NPs up to 1 mg / ml resulted in a notable stimulation of cell proliferation, with an increase of 158% compared to the control group.
[0051] The results obtained reveal the absence of significant toxicity of CuO-NPs, thus validating their safety in a medical context. This characteristic is crucial, as it indicates that the use of these nanoparticles in therapeutic or cosmetic applications does not pose risks to normal cells, thereby reinforcing their potential use in regenerative medicine and skincare.
[0052] Furthermore, these results suggest that CuO-NPs, at higher concentrations, can promote the proliferation of fibroblasts, key cells involved in the regeneration and repair of skin tissue. This mechanism of fibroblast proliferation stimulation could be exploited in innovative treatments such as the development of topical care or biomedical bandages based on nanoparticles, aimed at improving the healing of chronic wounds, burns, or post-surgical injuries by accelerating healing and facilitating connective tissue reconstruction.
[0053] Example 6: Anticoagulant activity of CuO-NPs produced by Inula viscosa
[0054] The anticoagulant activity of CuO-NPs biosynthesized from *Inula viscosa*, according to the process of the present invention, was evaluated using prothrombin time (PT) and partial activated partial thromboplastin time (PATT) tests, performed with the "Diagnostica Stago SO S" kit. Blood samples were first centrifuged to obtain platelet-poor plasma. In the PT test, the plasma was incubated with CuO-NPs at different concentrations (from 1 pg / ml to 1 mg / ml), without causing a significant change in clotting time, indicating that the extrinsic coagulation pathway was not affected. In contrast, the TCA test, which assesses the intrinsic coagulation pathway, revealed that CuO-NPs increased clotting time in a dose-dependent manner, reaching a maximum of 44.3 seconds at the highest concentration tested, although this increase was less than that observed with heparin (Table 1).
[0055] These results suggest that CuO-NPs act primarily on the intrinsic coagulation pathway, thus offering potential in the treatment of thrombotic disorders, particularly by facilitating wound healing processes while reducing excessive clot formation. Furthermore, these anticoagulant properties open up possibilities for the prevention of post-surgical thrombosis, reducing the risk of thromboembolic complications while optimizing wound healing. CuO-NPs could also be incorporated into medical devices, such as advanced wound dressings, to prevent local thrombosis while stimulating cell regeneration. Finally, these CuO-NPs could find applications in medical grafts and implants, by regulating the inflammatory response and promoting better tissue integration, while minimizing the risk of thrombosis around implanted devices.
[0056] Table 1: Anticoagulant activity of CuO-NPs from 'Inula viscosa'
[0057] > >
[0058]
[0059] Example 7: Anti-inflammatory activity of CuO-NPs produced by Inula viscosa
[0060] The anti-inflammatory properties of CuO-NPs synthesized from Inula viscosa were evaluated using the BSA denaturation inhibition assay. For this purpose, 100 µL of CuO-NPs, at concentrations ranging from 0.001 to 1 mg / mL, were added to 500 µL of 1% BSA solution (pH 6.8). The reaction mixture was incubated at 37°C for 20 minutes and then heated at 57°C for an additional 20 minutes. After cooling to room temperature, the absorbance was measured at 660 nm. Salicylic acid SA was used as a positive control in the present invention.
[0061] The results (Figure 7) showed that CuO-NPs inhibit BSA denaturation in a concentration-dependent manner, with inhibitions ranging from 20.80% to 43.26% at concentrations of 0.001 to 1 mg / ml. Salicylic acid exhibited similar inhibitions, with values ranging from 21.67% to 44.44% at the same concentrations. These results suggest that CuO-NPs possess anti-inflammatory properties comparable to those of salicylic acid, making them particularly suitable for the treatment of inflammatory wounds.
[0062] By reducing inflammation, CuO-NPs obtained from Inula viscosa can help promote wound healing and be used in active dressings. They can also be incorporated into cosmetic products such as creams, serums, or lotions for tissue regeneration and to reduce the signs of skin aging. Furthermore, these CuO-NPs can be used in medical or cosmetic devices for anti-inflammatory applications, particularly in the treatment of skin conditions such as eczema or psoriasis.
[0063] 2- Production of dressings impregnated with nanoparticles
[0064] Another aspect of the invention relates to the use of CuO-NPs obtained by the described process as therapeutic agents in the formulation of active dressings. These dressings, enriched with CuO-NPs, could not only promote wound healing but also protect against bacterial infections, thus offering effective solutions for the care of chronic wounds and burns.
[0065] Example 8: Impregnation of in situ dressings with synthesized CuO-NPs at
[0066]
[0067] viscosa
[0068] The integration of metallic nanoparticles into medical devices, particularly for wound treatment, is an innovative approach to improving their therapeutic properties, such as healing and antimicrobial capabilities. In this regard, dressings have been impregnated in situ with CuO-NPs obtained according to the present invention.
[0069] The sterile dressings were first immersed in approximately 200 ml of a 10 mM aqueous solution of CuSO4-5H2O and agitated at room temperature for at least one hour. Copper ion reduction was initiated by the dropwise addition of approximately 50 ml of aqueous plant extract, while maintaining constant agitation and temperature. The phytochemicals present in the extract facilitated the reduction of copper ions to CuO-NPs bound to the dressing fibers. After a 24-hour incubation, the mixture was heated to approximately 80°C for one hour to ensure complete reduction and fixation of the nanoparticles. The impregnated dressings were then carefully recovered, washed several times with distilled water to remove nanoparticles and unbound residues, and then dried at 60°C for 24 hours to ensure nanoparticle stability.
[0070] The formation of CuO-NPs was initially confirmed by a visible color change, with the treated dressings turning from white to brown. Morphological analysis of the treated dressings, performed by SEM, revealed a rough, hierarchical surface, in contrast to the smooth structure of untreated dressings (Figure 8). EDX analysis also highlighted a characteristic copper peak around 8 keV, confirming the presence of CuO-NPs on the dressings. This approach offers new perspectives for the design of improved dressings that promote wound healing and provide enhanced antimicrobial properties through the integration of CuO-NPs.
[0071] Example 9: Evaluation of the antimicrobial activity of CuO-NP impregnated dressings obtained from Inula viscosa
[0072] The antibacterial activity of CuO-NP-impregnated dressings was evaluated against three common bacterial strains responsible for wound infections: Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. After sterilizing the dressings, bacterial cultures were prepared in a nutrient medium and incubated for 24 hours at 37°C to allow bacterial growth. The bacterial suspension was then adjusted to meet McFarland standards, ensuring a standardized bacterial concentration for testing. Antibacterial efficacy was determined using a method similar to the Petri dish diffusion test, by cutting the dressings into 11 mm discs and placing them on Mueller-Hinton agar plates inoculated with the bacteria. After incubation at 37°C for 24 hours, the formation of zones of inhibition (ZOI) around the dressings indicated antibacterial efficacy.An untreated sterile dressing served as a negative control, while tobramycin (10 pg) was used as a positive control. Results showed no zone of interest (ZOI) for the untreated dressing, confirming the absence of antibacterial activity. In contrast, dressings impregnated with CuO-NPs exhibited significant antibacterial activity against the tested strains, as shown in Figure 9, with ZOIs of 18 mm against E. coli and 14 mm against P. aeruginosa, close to the results obtained with the positive control (19 mm and 12 mm, respectively). These results suggest that impregnating dressings with CuO-NPs enhances their antibacterial activity against bacteria responsible for wound infections, thus offering a potential solution for the treatment of chronic or infected wounds.
[0073] Industrial applications
[0074] The biosynthesized CuO-NPs from Inula viscosa according to the invention have broad application potential in numerous biomedical fields. Their low toxicity and favorable interaction with blood cells make them ideal candidates for innovative medical devices. They can be incorporated into advanced dressings and smart bandages used to treat chronic wounds, severe burns, or post-surgical injuries, promoting tissue regeneration, accelerating healing, and reducing the risk of infection. These dressings can also be designed to release medication in a controlled manner, thus contributing to optimal wound management.
[0075] CuO-NPs can also be used in medical devices such as stents, catheters, and implants, where their biocompatibility and ability to prevent infection and clot formation can improve the safety and efficacy of treatments. By regulating the inflammatory response and minimizing the risk of thrombosis around implants, they promote better integration of devices into tissues.
[0076] Furthermore, their potential in targeted drug delivery opens new avenues for complex treatments, particularly in cancer therapies. CuO-NPs could be used to deliver drugs or gene therapies directly to targeted cells, thereby reducing systemic side effects while maximizing therapeutic efficacy.
Claims
Demands 1. A process for synthesizing copper oxide nanoparticles (CuO-NPs) from parts of the Inula viscosa plant, characterized in that it comprises the following steps: • Mix a solution of copper sulfate pentahydrate with an extract of one of the parts of the Inula viscosa plant, ' • Shake the reaction mixture under optimal synthesis conditions until a color change is observed, going from yellow-green to dark brown, indicating the formation of CuO-NPs; • Separate the CuO-NPs obtained from the reaction mixture by centrifugation; • Wash and dry the nanoparticles to obtain CuO-NPs in powder form.
2. A process for the synthesis of CuO-NPs according to claim 1, wherein the reaction mixture is kept under stirring at a temperature between 20°C and 80°C, for a minimum of 30 minutes, until a significant color change is observed.
3. The CuO-NPs obtained according to the processes of claims 1 and 2, characterized in that they exhibit biocompatible, anticoagulant, anti-inflammatory, healing properties and significant antibacterial activity against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
4. The CuO-NPs according to claim 3, characterized in that said nanoparticles have a predominantly spherical shape with a size between 50 and 110 nm 5. Use of CuO-NPs prepared according to claims 1 and 2 as an anticoagulant agent in medical devices such as catheters, prostheses, or infusion devices, to prevent the formation of blood clots 6. Use of CuO-NPs prepared according to claims 1 and 2 as a healing and antibacterial agent in active medical dressings to promote wound healing while protecting against bacterial infections.
7. Use of CuO-NPs according to claim 6 in medical devices, such as dressings, bandages, creams, gels, or any other medical coating, intended to promote wound healing, treat burns, and protect against bacterial infections.
8. Use of CuO-NPs according to any one of the preceding claims in cosmetic products, such as creams, serums or lotions contributing to tissue regeneration and the reduction of skin aging. Use of CuO-NPs according to any one of the preceding claims in medical or cosmetic devices for anti-inflammatory applications to reduce local inflammatory reactions, particularly in the treatment of skin conditions such as eczema or psoriasis.